NYKAA Cup and hndle pattern Breakout Chart

MOREPENLAB CUP & HANDLE PATTERN BREAKOUT Analysis

      Technical Analysis 

•  Market Cap                   ₹ 2,904 Cr.
•  Current Price               ₹ 56.8
  
•  High / Low                    ₹ 57.8 / 28.5
  
•  Stock P/E                          30.2
  
•  Book Value                   ₹ 16.6
  
• Dividend Yield                0.00 %
  
• ROCE                                 16.8 %
  
• ROE                                   12.0 %
  
• Face Value                    ₹ 2.00
  
• Industry PE                      33.3
  
• Promoter holding           38.2 %
  
• Pledged percentage        0.00 %
  
• Debt to equity                  0.03
  
• Profit Prev 12M           ₹ 76.1 Cr.
  
• EPS                                 ₹ 1.88
  
• Price to book value       3.43
  
• EVEBITDA                       16.7
  
• Price to Earning             30.2
• No. Eq. Shares                51.1Cr.

 About

The company Morepen Laboratories Ltd. is in the business of creating, developing, manufacturing, and distributing a variety of home health products as well as branded and generic formulations of active pharmaceutical ingredients (APIs)

DAILY TIME FRAME CHART

Main-Point

Asthmatic medication leadership

As one of the biggest suppliers of the asthma medication monteplaza sodium (85 MT), the company leads the world in both loratadine (140 MT) and this other medication. Among the medications it produces commercially are Atorvastatin Calcium (120 MT), Rosuvastatin Calcium (anti-hypercholesterolemic series), Fexofenadine Hydrochloride (antihistamine series), Olmesartan (anti-hypertensive series), and their intermediates.

WEEKLY TIME FRAME CHART

Business Segment

API Segment

The business is well-known in both the domestic and internal API markets. With the biggest capacity for four APIs in the world, it has a discerning portfolio. More than 800 clients are served globally, with a significant portion coming from Asia and India. Its carefully curated offering encompasses anti-allergy, cardiac, neuro, and diabetic treatment.

Home Diagnostics

A variety of point-of-care diagnostic tools, including air purifiers, stethoscopes, thermometers, breathe-free vaporizers, glucose meters, and BP monitors, are sold by the corporation under this category. Over the course of 9 months in FY24, the company has sold around 1470 million Gluco Strips and installed over 11.2 million Gluco Monitors.

New Therapeutic Segment

Additionally, it plans to join the anti-cancer market by evaluating the development of a number of viable contenders, some of which include important drugs like Axitinib, Enzalutamide, Abemaciclib, Palbociclib, Olaparib, and Ibrutinib.

Geographical Revenue Breakup 9MFY24
India : 33%
International : 67%

Focus

In preparation for future expansion, the company is expanding both its API and medical device capacities. It is developing anti-cancer and anti-arthritis medications under the therapeutic sector.